Patients are sought for a clinical study to determine

September 17, 1998

September 17, 1999--Hormone replacement therapy has been shown to protect women against heart disease, stroke and Alzheimer's disease. Now, researchers at Rush-Presbyterian-St. Luke's Medical Center have begun a clinical trial to determine if estrogen also improves the effectiveness of drugs used to treat Parkinson's patients.

Currently the most common treatment for Parkinson's patients is a daily regimen of the drug Levodopa. While many patients benefit from consistent use of Levodopa, the effects of the drug wear off after two or three hours, creating a "roller coaster" effect. Recently, a drug called Mirapex has proven effective at leveling these ups and downs, and preliminary information suggests hormone replacement therapy can enhance these effects.

Dr. Aikaterini Kompoliti, a neurologist at Rush-Presbyterian-St. Luke's Medical Center, is heading a team of researchers investigating whether estrogen can extend this period of effectiveness and further smooth out the ups and downs caused by Levodopa.

Rush is one of two medical centers taking part in this double-blind, placebo trial that will study 36 patients. The other center is the Mayo Clinic in Scottsdale, Ariz.

Parkinson's occurs when the brain cannot produce enough dopamine, causing patients to lose the ability to control their own movements. Levodopa and Mirapex are dopamine agonists that work by fooling the brain into thinking that dopamine exists. When effective, these medications allow patients to regain some control over their motor functions.

"Our hypothesis is that estrogen will work with the Mirapex and Levodopa to increase and enhance the effectiveness of both drugs," said Kompoliti. Each medical center in the trial will treat 18 patients who are already on Levodopa: six will be men on Levodopa; six will be post-menopausal women on Levodopa, but not estrogen; and six will be post-menopausal women on Levodopa and estrogen. All patients will be started on Mirapex or a placebo. Both patients and researchers will be blinded. (Neither patients nor doctors will know if patients are on Mirapex or placebo.) The medication will be given for two months. Every female participant will receive a complete gynecological exam as well as a free mammogram. At the end of the trial, every patient will receive a year's supply of Mirapex, from Pharmacia & Upjohn, Inc. Pharmacia & Upjohn Inc. manufactures Mirapex and is the sponsor of this clinical trial.
To participate in the study, patients must have advanced Parkinson's disease. Interested parties should call 312-942-5936.

Rush-Presbyterian-St. Luke's Medical Center includes the 809-bed Presbyterian-St. Luke's Hospital; 154-bed Johnston R. Bowman Health Center for the Elderly; Rush University (Rush Medical College, College of Nursing, College of Health Sciences and Graduate College); and seven Rush Institutes providing diagnosis, treatment and research into leading health problems. The medical center is the tertiary hub of the Rush System for Health, a comprehensive healthcare system capable of serving about three million people through its outpatient facilities and eight member hospitals.

Rush University Medical Center

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to